Comparing Medications for Adults With Type 2 Diabetes
Intermediate Outcomes: Overview of Weight Results
Diabetes medications varied in their effects on body weight. Weight change was small to moderate, generally less than 2 kg, between baseline and final values. However, even small amounts of weight gain (5 percent to 10 percent of body weight) may be associated with increased insulin resistance. Metformin consistently had a more favorable effect on weight when compared with other diabetes medications such as thiazolidinediones, sulfonylureas, and DPP-4 inhibitors. Although placebo-controlled trials of metformin were excluded from this review, the 2007 evidence report showed that metformin was associated with weight neutrality when compared with placebo. As compared with sulfonylureas, the GLP-1 receptor agonists were associated with a relative weight change of about -2.5 kg, with a moderate strength of evidence. Metformin plus second-generation sulfonylureas are associated with less weight gain than are combinations with TZDs (moderate strength of evidence). Some newer agents in combination show promise for lower levels of weight gain (low strength of evidence). The UKPDS, while consistent with the above meta-analysis, was excluded from this section of the report since they were allowed to add other diabetes medications to their initial monotherapy groups.
Keywords: intermediate outcomes | body weight | overview of results | monotherapy | combination therapy | type 2 diabetes
- Barrera JG, D’Alessio DA, Drucker DJ, et al. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 2009;58(12):2820-2827.
- Bennett WL, Wilson LM, Bolen S, et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update. Comparative Effectiveness Review No. 27. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) AHRQ Publication No. 11-EHC038-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011. Available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=644.
- Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-2443.
- Turner R, Murchison L, Wright AD, et al. United Kingdom prospective diabetes study 24: A 6- year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128(3):165-175.
- UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-865.
- United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non- insulin dependent diabetes followed for three years. BMJ 1995;310(6972):83-88.
- Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006;55(12):3387-3393.
- Kahn BB, Flier JS. Obesity and insulin resistance. J. Clin. Invest. 2000;106(4):473-481.
Your slide tray is being processed.